Potential solutions for manufacture of CAR T cells in cancer immunotherapy
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.
Main Authors: | Ulrich Blache, Georg Popp, Anna Dünkel, Ulrike Koehl, Stephan Fricke |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-09-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-32866-0 |
Similar Items
-
CAR T cells for treating autoimmune diseases
by: Dimitrios Mougiakakos, et al.
Published: (2023-11-01) -
Production and Application of CAR T Cells: Current and Future Role of Europe
by: Vladan Vucinic, et al.
Published: (2021-08-01) -
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
by: Ulrich Blache, et al.
Published: (2021-05-01) -
CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
by: Ioana Sonya Ciulean, et al.
Published: (2023-11-01) -
Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
by: Katharina Eva Ruppel, et al.
Published: (2022-03-01)